|
21.01.2025 15:39:03
|
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.
Following the announcement, Replimune's stock is currently climbing 26.09 percent, to $12.78 on the Nasdaq.
Replimune said RP1 is intended to maximize tumor-killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response.
The acceptance is based on the primary analysis data of the IGNYTE trial, investigating the combined therapy in adults with anti-PD-1 failed melanoma.
Replimune had received Breakthrough Therapy designation for RP1 in combination with nivolumab for the treatment of advanced melanoma.
Analysen zu Replimune Group Inc Registered Shs
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Replimune Group Inc Registered Shs | 11.84 | 16.88% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
SMI im Plus -- DAX höher - neues Rekordhoch -- Asiens Börsen letztlich mehrheitlich in RotDer heimische sowie der deutsche Aktienmarkt zeigen sich am Mittwoch mit Gewinnen. Der DAX erreicht dabei sogar eine neue Bestmarke. Die Börsen in Fernost notierten zur Wochenmitte überwiegend im Minus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |